MARKET

CHRS

CHRS

Coherus Bioscien
NASDAQ
1.030
0.000
0.00%
Closed 19:10 04/28 EDT
OPEN
1.020
PREV CLOSE
1.030
HIGH
1.050
LOW
0.9776
VOLUME
1.64M
TURNOVER
--
52 WEEK HIGH
2.430
52 WEEK LOW
0.6603
MARKET CAP
119.37M
P/E (TTM)
4.148
1D
5D
1M
3M
1Y
5Y
1D
Coherus Biosciences presents data from Phase 1 dose expansion study of CHS-114
TipRanks · 21h ago
Coherus Biosciences: Data From Ongoing Phase 1 Clinical Trial Evaluating CHS-114 Shows Clinical Efficacy And Proof Of Mechanism In HNSCC In Combination With toripalimab
Benzinga · 21h ago
Weekly Report: what happened at CHRS last week (0421-0425)?
Weekly Report · 1d ago
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
Barchart · 1d ago
Coherus Biosciences Board Member Stolper Steps Down
TipRanks · 3d ago
Coherus BioSciences Is Maintained at Neutral by UBS
Dow Jones · 4d ago
Coherus BioSciences Price Target Cut to $1.05/Share From $1.50 by UBS
Dow Jones · 4d ago
Coherus Biosciences price target lowered to $1.05 from $1.50 at UBS
TipRanks · 4d ago
More
About CHRS
More
Coherus BioSciences, Inc. is a commercial-stage oncology company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its commercial product, LOQTORZI (toripalimab-tpzi), is a programmed death receptor-1 (PD-1) monoclonal antibody that blocks PD-1 ligands PD-L1 and PD-L2 with high potency. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in three ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a cytolytic anti-CCR8 antibody which is in Phase I study in patients with advanced solid tumors. CHS-1000 is a humanized Fc-modified IgG1 monoclonal antibody targeting ILT4.
Recently
Symbol
Price
%Change

Webull offers Coherus Biosciences Inc stock information, including NASDAQ: CHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CHRS stock methods without spending real money on the virtual paper trading platform.